Discover
ENLV
Enlivex Ltd.
0.54
2 x 0.40
2 x 0.69
bid
ask
-
0.01
1.51%
2 @ 07:17 AM
0.54 -0.00 (0.52%)
| Ytd | -22.96% | |
| 1y | -51.64% |
0.52
day range
0.59
0.52
52 week range
2.10
| Open | 0.59 | Prev Close | 0.55 | Low | 0.52 | High | 0.59 | Mkt Cap | 130.55M |
| Vol | 684.89K | Avg Vol | 433.07K | EPS | 25.48 | P/E | 0.02 | Forward P/E | -2.14 |
| Beta | 1.10 | Short Ratio | 0.56 | Inst. Own | 18.81% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-30 | 50-d Avg | 0.74 | 200-d Avg | 0.94 | 1yr Est | 9.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-29 | 2024-09 | -0.16 | -0.12 | 0.04 | 25.00% |
| 2024-08-30 | 2024-06 | -0.22 | -0.16 | 0.06 | 27.27% |
| 2024-06-14 | 2024-03 | -0.25 | -0.22 | 0.03 | 12.00% |
| 2024-03-29 | 2023-12 | 0 | -0.48 | N/A | N/A |
| 2023-11-09 | 2023-09 | -0.32 | -0.32 | N/A | N/A |
| 2023-09-01 | 2023-06 | -0.43 | -0.37 | 0.06 | 13.95% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-11 | D. Boral Capital | Upgrade | Buy | Buy |
| 2024-12-03 | D. Boral Capital | Upgrade | Buy | Buy |
| 2024-11-14 | D. Boral Capital | Upgrade | Buy | Buy |
| 2024-09-27 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-26 | EF Hutton | Upgrade | Buy | Buy |
| 2024-09-24 | EF Hutton | Upgrade | Buy | Buy |
Profile
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Armistice Capital, LLC | 2.14M | 2.65M | 11.52% |
| 2024-09-29 | Morgan Stanley | 245.75K | 304.73K | 1.32% |
| 2024-09-29 | Renaissance Technologies, LLC | 74.79K | 92.74K | 0.40% |
| 2024-09-29 | Sigma Investment Counselors Inc | 30.00K | 37.20K | 0.16% |
| 2024-09-29 | Xtx Topco Ltd | 22.66K | 28.10K | 0.12% |
| 2024-09-29 | Goldman Sachs Group Inc | 13.94K | 17.28K | 0.08% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 10.42K | 12.92K | 0.06% |
Split
| Split | Date |
|---|---|
| 1 : 8 | 2019-03-06 |
| 1 : 5 | 2017-09-25 |